Reactivity of thrombocytopenia PPPs with chemically distinct IIb/IIIa antagonists
| . | A264 . | 307 . | 330 . |
|---|---|---|---|
| 739758 | 100 | 8 | 36 |
| 734217 | 0 | 5 | 0 |
| 738167 | 60 | 0 | 0 |
| Roxifiban* | 0 | 100 | 100 |
| Sibrafiban* | 0 | 0 | 0 |
| Orbofiban* | 0 | 70 | 6 |
| . | A264 . | 307 . | 330 . |
|---|---|---|---|
| 739758 | 100 | 8 | 36 |
| 734217 | 0 | 5 | 0 |
| 738167 | 60 | 0 | 0 |
| Roxifiban* | 0 | 100 | 100 |
| Sibrafiban* | 0 | 0 | 0 |
| Orbofiban* | 0 | 70 | 6 |
The reactivity of thrombocytopenia PPPs with chemically distinct GP IIb/IIIa antagonists was tested in the improved DDAB ELISA version. The reactivity (delta) toward the antagonist that was dosed during the thrombocytopenia episode is set as 100%. The reactivity with the other antagonists is expressed as percentage of the maximal response (delta) observed with the GP IIb/IIIa antagonist dosed during thrombocytopenia (indicated by boldface type).
Name designates prodrugs; in vitro experiments were performed with the active forms.